Lilly cancer drug fails key trial, will no longer be prescribed

Eli Lilly and Co said on Friday that its cancer treatment Lartruvo, which had won conditional approval, failed to improve patient survival in a long-term confirmatory study and will no longer be prescribed, driving the drugmaker's shares down nearly 3 percent.

from Reuters: U.S. https://reut.rs/2R28q8M